Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498654 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects
A Phase 2 study, sponsored by Avant Immunotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00498654 is a Phase 2 study that has completed, run by Avant Immunotherapeutics. The registered enrollment target is 180 participants.
The verdict
NCT00498654, a Phase 2 study, has completed, sponsored by Avant Immunotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.
Interventions
- BIOLOGICAL Ty800 (Salmonella typhi) Oral Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00498654
The ClinicalTrials.gov registry entry for NCT00498654 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avant Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ty800 (Salmonella typhi) Oral Vaccine is the first listed.
NCT00498654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00498654 about?
NCT00498654 is a clinical study titled "Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects". The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.
What is the current status of trial NCT00498654?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2007-07. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00498654?
The interventions under investigation include: Ty800 (Salmonella typhi) Oral Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00498654?
This trial is sponsored by Avant Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.